As can be seen, the tested product was efficient on average against 56% bacterial strains,
while the highest activity was observed against the most wide-spread and dangerous pathogens E. coli, S. enteritidis, S. typhimurium, and Clostridium spp. Thus, in vivo health-protective and performance-improving activities of Bio-Mos® described in the cited articles, was fully corroborated by the performed in vitro tests. Recently, the agglutinating capacity towards
various enteric pathogens was compared for Bio-Mos® and several other mannose-containing compounds (Newman, 2006) using the specifically designed aggregation rate coefficient (ARC) method. The results of ARC assay demonstrated superior efficacy of BioMos® in binding and agglutination of bacteria.